Tina-quant® Cystatin C Gen. 2
Supporting the early detection of chronic kidney disease
- Cystatin C is an aid for physicians to detect early chronic kidney diseases (stages 1 & and 2) and provides patients with an improved prognosis
- The aim of therapy is to slow disease progression to stage 5 (ESRD) and the sooner treatment is initiated, the greater the benefit
- Cystatin C is a better and earlier indicator of mild changes in eGFR, when creatinine values are still within the normal range
- Cystatin C-based GFR assessments can make a real difference with respect to patient outcome - diagnosing chronic kidney disease at an early stage can add two or more years of ESRD-free survival and, in some patients, ESRD may actually be prevented
Earlier and more reliable assessment of renal function
- Cystatin C is a more reliable, early marker of renal dysfunction compared with creatinine
- Early detection and treatment can prevent or delay adverse outcomes of renal failure
- Cystatin C is a better indicator of mild changes in GFR - at which stage creatinine values are still within the normal range
Benefits for the lab
- Cystatin C concentration is not influenced by inflammation, muscle mass, gender or age
- Standardized to the international reference material ERM-DA 471/IFCC
- Long onboard stability and calibration frequency mean economical reagent usage and cost efficiencies
Studies demonstrate that the progression of end stage renal disease may be delayed or prevented:
National Kidney Disease Education Program, “Chronic Kidney Disease in the United States”, Presentation page 23.
More than 11 million patients in US may go undetected with creatinine-based GFR assessments due to creatinine-blind area:
Coresh, J., Byrd-Holt, D., Astor, B.C., Briggs, J.P., Eggers, P.W., Lacher, D.A., Hostetter, T.H. (2005). Chronic kidney disease awareness, prevalence, and trends among US adults, 1999 to 2000. J Am Soc Nephrol. 16, 180–188.
Number of US Patients suffering chronic kidney disease (CKD); about 26 million American adults of the general population. More than 11 million patients in US may go undetected with creatinine-based GFR assessments due to creatinine-blind area.